Hansel Tookes
Infectious Disease · Miami, FLNPI 1942628904
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,621 of the $1,939 with a category attached, or 83.6%. Gilead accounts for 92.5% of it on its own, with 2 other manufacturers making up the rest. 2023 is the largest year on record at $1,693, more than ten times the $102 reported in 2019.
Across 8 payments — averaging $242.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Angiodynamics, Inc.$129
- Viiv Healthcare Company$15
Across 12 payments — averaging $64,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$769K
What the payments were for
- Travel & lodging$1,62184%
- Food & beverage$31916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 6 | $1,795 |
| Angiodynamics, Inc. | 1 | $129 |
| Viiv Healthcare Company | 1 | $15 |
How this compares
$1,939 in reported general payments places this provider in the 65th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 121 | $479,424 |
| RukobiaFostemsavir Tromethamine | 11 | $99,613 |
| TivicayDolutegravir Sodium | 13 | $39,336 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $22,824 |
| OzempicSemaglutide | 12 | $11,514 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $9,849 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $616 |
| Gabapentin | 53 | $497 |
| Triamcinolone Acetonide | 13 | $386 |
| Mirtazapine | 41 | $261 |
| Rosuvastatin Calcium | 27 | $172 |
| Clonazepam | 17 | $113 |
| Tamsulosin Hcl | 21 | $90 |
| Atorvastatin Calcium | 32 | $84 |
| Losartan Potassium | 20 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,795 | $502,248132 claims |
| Viiv Healthcare CompanyRukobia, Tivicay | $15 | $138,95024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Miami
- Douglas BrustMiami$359K
- Dushyantha JayaweeraMiami$98K
- Ricardo FrancoMiami$96K
- Lilian AbboMiami$61K
- Jorge MurilloMiami$53K
- Thomas HootonMiami$42K
- Gilberto Torres-MadrizMiami$42K
- Vanessa SilebiMiami$32K
- Hector BolivarMiami$25K
- Jose Camargo GalvisMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.